Axsome Therapeutics (AXSM) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 5, 2026, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 4, 2026.

Voting matters and shareholder proposals

• Election of two directors: Mark Saad and Susan Mahony, Ph.D., MBA, with board recommending a vote in favor.

• Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.

• Advisory vote to approve executive compensation, with board recommending approval.

• Other business may be addressed as appropriate during the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends all proposals, including director nominees and auditor ratification.